All In Biotech

Drug Trial Radar · NCT01673438

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL Administered as Infusions Every 3 Weeks in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Feb 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Jul 2012

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Aug 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b open-label study to investigate the safety and maximum tolerated dose of aldoxorubicin plus doxorubicin HCl adminstered as infusion every 3 weeks for up to 8 cycles in subjects with advance solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • aldoxorubicinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.